Bextra Drug Lawyer

What is Bextra?

Bextra is a drug named Valdecoxib which is used in the treatment of rheumatoid arthritis, osteoarthritis and painful menstruations.  The drug was approved by the United States food and drug administration on November 20, 2001. Until 2005, Bextra was available in tablet form but initially it was removed from the market due to increased risks of heart attack and stroke.

 

Valdecoxib is a prescription drug used in the treatment of osteoarthritis rheumatoid arthritis and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug or NSAID and should not be taken by anyone allergic to these types of medications.

 

It was withdrawn from the US market in 2005. The Bextra settlement was entered into by and among the US and it was reported that Pfizer, Inc. began discussing settlement for some Celebrex and Bextra lawsuits pending throughout the United States.

 

It has been advised that one should not take Bextra without first concerning to your doctor. The symptoms of taking Bextra can be measured. So if you experience abdominal pain, tenderness or discomfort; nausea, bloody vomit, black or tarry stools you should immediately notify your doctor. One of the main precautions that should be taken in this case is that if you have been or are being treated for pain associated with CABG. You should definitely consult your doctor.

 

If you want the assistance of Bextra attorneys or Bextra lawyers for a case review you should approach us for assistance. We have an experienced team of Bextra attorneys and you can consult us anytime for the correct advice.

Side Effects And Withdrawals Of Bextra.

On April 7 2005 Pfizer withdrew Bextra from the US market on recommendation by the FDA citing an increased risk of heart attack and stroke and also the risk of a serious sometimes fatal skin reaction. This was a result of recent attention to prescription NSAIDs such as Merck’s Vioxx. Other reported side-effects were angina and Stevens-Johnson syndrome.

 

Pfizer first acknowledged cardiovascular risks associated with Bextra in October of 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

criminal attorney
criminal law attorney
criminal case attorney
case study attorney

Personal Injury Related To Bextra:

With the removal of the drug from the market, there is expected to be a surge in Personal Injury Claims, many in the form of class action, to seek compensation.

 

FDA has requested that Pfizer voluntarily withdraw Bextra from the United States market. Pfizer has agreed to suspend sales and marketing of Bextra in the United States, pending further discussion with the Agency. At this time, the Agency has concluded that the overall risk versus benefit profile of Bextra is unfavorable. This conclusion is based on the potential increased risk for serious cardiovascular (CV) adverse events, which appears to be a class effect of non-steroidal anti-inflammatory drugs (NSAIDs) (excluding aspirin), an increased risk of serious skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme) compared to other NSAIDs, and the fact that Bextra has not been shown to offer any unique advantages over the other available NSAIDs.

 

Recommendation

FDA recommends that patients being treated with Bextra be switched to an alternative therapy.

 

Data Summary

  • Bextra has been demonstrated to be associated with an increased risk of serious adverse CV events in two short-term trials in patients immediately post-operative from coronary artery bypass graft (CABG) surgery. Data are not available from long-term controlled clinical trials to evaluate the cardiovascular safety of Bextra following chronic use. FDA has concluded that it is reasonable to extrapolate the adverse CV risk information for Bextra from the short-term CABG trials to chronic use given the fact that other COX-2 selective NSAIDs have been shown in long-term controlled clinical trials to be associated with an increased risk of serious adverse CV events (e.g., death, MI, stroke), and the well described risk of serious, and often life-threatening gastrointestinal bleeding.
  • Bextra is a sulfonamide and already carries a boxed warning in the package insert for serious and potentially life-threatening skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme). The reporting rate to FDA’s spontaneous reporting system for these serious skin reactions is significantly greater for Bextra than other COX-2 selective agents. The risk of these serious skin reactions in individual patients is unpredictable, occurring in patients with and without a history of sulfa allergy, and after both short- and long term use.
  • To date, there have been no studies that demonstrate an advantage of Bextra over other NSAIDs that might offset the concern about these serious skin risks, such as studies that show a GI safety benefit, better efficacy compared to other products, or efficacy in a setting of patients who are refractory to treatment with other products.
  • Extensive data related to the cardiovascular safety of Bextra and other COX-2 selective and non-selective NSAIDs were presented at the Joint Meeting on February 16, 17, and 18, 2005, of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

Find Bextra Drug Attorney by Location

Atlanta

Austin

Baltimore

Boston

Charlotte

Chicago

Cleveland

Columbus

Dallas

Denver

Detroit

Houston

Indianapolis

Jacksonville

Kansas City

Las Vegas

Los Angeles

Miami

Milwaukee

Minneapolis

Nashville

New York

Oklahoma City

Orlando

Philadelphia

Phoenix

Portland

Raleigh

St. Louis

San Antonio

San Diego

San Francisco

San Jose

Seattle

Tampa

Washington, DC

Find Bextra Drug Attorney in Top Counties

Alameda County, CA

Bexar County, TX

Broward County,  FL

Cook County, IL

Cuyahoga County, OH

Dallas County, TX

Harris County, TX

King County, WA

Kings/ Brooklyn County, NY

Los Angeles County, CA

Maricopa County, AZ

Miami-Dade County, FL

New York/ Manhattan County, NY

Orange County, CA

Philadelpia County, PA

Queens County, NY

Riverside County, CA

San Bernardino County, CA

San Diego County, CA

Santa Clara County, CA

Suffolk County, NY

Tarrant County, TX

Wayne County, MI

Find Bextra Drug Attorney in Top Metros

Chicago Metro, IL

Los Angeles-Long Beach Metro, CA

New York Metro, NY

Washington Metro, DC-MD-VA-WV

Find Bextra Drug Attorney By State

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Iowa

Indiana

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New Mexico

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Wyoming